TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive The Raghavan Experiment: With $500 Million to Draw On, An Iconoclast Invents Rational Care for a Gigantic System January 4, 2013
TCL Archive NCI Seen Shifting Away From Comprehensive Center Emphasis Toward Encouraging Clinical Excellence April 30, 1976
